MovDisordV3, Ncbi, Curation, bibRecord, 004D38

Sleep benefit in Parkinson's disease.

Identifieur interne : 004D38 ( Ncbi/Curation ); précédent : 004D37; suivant : 004D39

Sleep benefit in Parkinson's disease.

Auteurs : M. Merello [Argentine] ; A. Hughes ; C. Colosimo ; M. Hoffman ; S. Starkstein ; R. Leiguarda

Source :

Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 1997.

RBID : pubmed:9251067

English descriptors

KwdEn :
- Aged, Antiparkinson Agents (pharmacology), Circadian Rhythm (drug effects), Female, Humans, Levodopa (pharmacology), Male, Middle Aged, Motor Activity (drug effects), Parkinson Disease (drug therapy), Parkinson Disease (physiopathology), Prospective Studies, Questionnaires, Sleep (drug effects), Time Factors.
MESH :
- chemical , pharmacology : Antiparkinson Agents, Levodopa.
- drug effects : Circadian Rhythm, Motor Activity, Sleep.
- drug therapy : Parkinson Disease.
- physiopathology : Parkinson Disease.
- Aged, Female, Humans, Male, Middle Aged, Prospective Studies, Questionnaires, Time Factors.

Abstract

Sleep benefit (SB) In Parkinson's disease (PD) is not well characterized. To determine SB frequency, as well as to characterize and correlate it with other disease variables, we evaluated prospectively a consecutive series of 312 PD patients by means of a structured questionnaire: 55% reported having SB and 35% reported that awakening was their best time of the day. Because of SB, 21% of the entire population were able to skip or delay medication. The mean duration of the phenomenon was 85.4 +/- 67 min. Patients with SB were significantly older (p < 0.0002), had disease longer (p < 0.05), and were often men (chi 2 = 3.5, df 1, p = 0.05). Patients with SB took sleep medication with similar frequency as those without SB. There were no differences in hours of sleep or sleep latency. Sleep problems such as nightmares or somnambulism, but not the number of sleep awakenings, were similar in both groups. In conclusion, SB is a frequent phenomenon, especially in men, elderly patients, and patients with longer disease duration. SB enables the morning L-dopa dose to be postponed in approximately 50% of patients.

DOI: 10.1002/mds.870120405
PubMed: 9251067

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :004645
to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :004645
to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :004573
to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :004D38

Links to Exploration step

pubmed:9251067

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Sleep benefit in Parkinson's disease.</title>
<author><name sortKey="Merello, M" sort="Merello, M" uniqKey="Merello M" first="M" last="Merello">M. Merello</name>
<affiliation wicri:level="1"><nlm:affiliation>Movement Disorders Section, Institute for Neurological Research, Raul Carrea FLENI, Buenos Aires, Argentina.</nlm:affiliation>
<country xml:lang="fr">Argentine</country>
<wicri:regionArea>Movement Disorders Section, Institute for Neurological Research, Raul Carrea FLENI, Buenos Aires</wicri:regionArea>
<wicri:noRegion>Buenos Aires</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hughes, A" sort="Hughes, A" uniqKey="Hughes A" first="A" last="Hughes">A. Hughes</name>
</author>
<author><name sortKey="Colosimo, C" sort="Colosimo, C" uniqKey="Colosimo C" first="C" last="Colosimo">C. Colosimo</name>
</author>
<author><name sortKey="Hoffman, M" sort="Hoffman, M" uniqKey="Hoffman M" first="M" last="Hoffman">M. Hoffman</name>
</author>
<author><name sortKey="Starkstein, S" sort="Starkstein, S" uniqKey="Starkstein S" first="S" last="Starkstein">S. Starkstein</name>
</author>
<author><name sortKey="Leiguarda, R" sort="Leiguarda, R" uniqKey="Leiguarda R" first="R" last="Leiguarda">R. Leiguarda</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="1997">1997</date>
<idno type="RBID">pubmed:9251067</idno>
<idno type="pmid">9251067</idno>
<idno type="doi">10.1002/mds.870120405</idno>
<idno type="wicri:Area/PubMed/Corpus">004645</idno>
<idno type="wicri:Area/PubMed/Curation">004645</idno>
<idno type="wicri:Area/PubMed/Checkpoint">004573</idno>
<idno type="wicri:Area/Ncbi/Merge">004D38</idno>
<idno type="wicri:Area/Ncbi/Curation">004D38</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Sleep benefit in Parkinson's disease.</title>
<author><name sortKey="Merello, M" sort="Merello, M" uniqKey="Merello M" first="M" last="Merello">M. Merello</name>
<affiliation wicri:level="1"><nlm:affiliation>Movement Disorders Section, Institute for Neurological Research, Raul Carrea FLENI, Buenos Aires, Argentina.</nlm:affiliation>
<country xml:lang="fr">Argentine</country>
<wicri:regionArea>Movement Disorders Section, Institute for Neurological Research, Raul Carrea FLENI, Buenos Aires</wicri:regionArea>
<wicri:noRegion>Buenos Aires</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hughes, A" sort="Hughes, A" uniqKey="Hughes A" first="A" last="Hughes">A. Hughes</name>
</author>
<author><name sortKey="Colosimo, C" sort="Colosimo, C" uniqKey="Colosimo C" first="C" last="Colosimo">C. Colosimo</name>
</author>
<author><name sortKey="Hoffman, M" sort="Hoffman, M" uniqKey="Hoffman M" first="M" last="Hoffman">M. Hoffman</name>
</author>
<author><name sortKey="Starkstein, S" sort="Starkstein, S" uniqKey="Starkstein S" first="S" last="Starkstein">S. Starkstein</name>
</author>
<author><name sortKey="Leiguarda, R" sort="Leiguarda, R" uniqKey="Leiguarda R" first="R" last="Leiguarda">R. Leiguarda</name>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="1997" type="published">1997</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Antiparkinson Agents (pharmacology)</term>
<term>Circadian Rhythm (drug effects)</term>
<term>Female</term>
<term>Humans</term>
<term>Levodopa (pharmacology)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Motor Activity (drug effects)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (physiopathology)</term>
<term>Prospective Studies</term>
<term>Questionnaires</term>
<term>Sleep (drug effects)</term>
<term>Time Factors</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Circadian Rhythm</term>
<term>Motor Activity</term>
<term>Sleep</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Prospective Studies</term>
<term>Questionnaires</term>
<term>Time Factors</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Sleep benefit (SB) In Parkinson's disease (PD) is not well characterized. To determine SB frequency, as well as to characterize and correlate it with other disease variables, we evaluated prospectively a consecutive series of 312 PD patients by means of a structured questionnaire: 55% reported having SB and 35% reported that awakening was their best time of the day. Because of SB, 21% of the entire population were able to skip or delay medication. The mean duration of the phenomenon was 85.4 +/- 67 min. Patients with SB were significantly older (p < 0.0002), had disease longer (p < 0.05), and were often men (chi 2 = 3.5, df 1, p = 0.05). Patients with SB took sleep medication with similar frequency as those without SB. There were no differences in hours of sleep or sleep latency. Sleep problems such as nightmares or somnambulism, but not the number of sleep awakenings, were similar in both groups. In conclusion, SB is a frequent phenomenon, especially in men, elderly patients, and patients with longer disease duration. SB enables the morning L-dopa dose to be postponed in approximately 50% of patients.</div>
</front>
</TEI>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004D38 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 004D38 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Ncbi
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:9251067
   |texte=   Sleep benefit in Parkinson's disease.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i   -Sk "pubmed:9251067" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a MovDisordV3

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Sleep benefit in Parkinson's disease.

Sleep benefit in Parkinson's disease.

Source :

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki